Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.

Authors

null

Jordi Bruix

BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain

Jordi Bruix , Philippe Merle , Alessandro Granito , Yi-Hsiang Huang , Gyorgy Bodoky , Marc Pracht , Osamu Yokosuka , René Gerolami , Gianluca Masi , Paul J. Ross , Shukui Qin , Tianqiang Song , Jean-Pierre Bronowicki , Isabelle Ollivier-Hourmand , Masatoshi Kudo , Marie-Aude Le Berre , Gerold Meinhardt , Guohong Han

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Prevention, Diagnosis, and Screening

Clinical Trial Registration Number

NCT01774344

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 229)

DOI

10.1200/JCO.2017.35.4_suppl.229

Abstract #

229

Poster Bd #

A7

Abstract Disclosures